About

Kinomica Limited is an exciting new spin-out from Barts Cancer Institute, Queen Mary University of London, UK.

We have developed KinoScan™, a powerful suite of advanced proprietary bioinformatic and phosphoproteomic analytical methods, for direct activity measurements of multiple endogenous kinases, thus comprehensive cell signaling pathway coverage.

We offer KinoScan™ to Pharma for: i). improved monitoring of drug molecular efficacy and response (i.e. fully elucidate mode of action & mechanisms of resistance); ii). discovery of superior clinical trial patient selection & stratification biomarkers.